DrugBank ID:

DB01264

Description:

Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well asritonavirfor the effective management of HIV-1 infection.As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.It was initially approved by the FDA in 2006.Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection.Clinical trials are underway and are expected to conclude in August 2020. [DrugBank]

Targets:

Human immunodeficiency virus type 1 protease (Human immunodeficiency virus 1) [DrugBank]

Pharmacodynamics:

Darunavir is an inhibitor of the human immunodeficiency virus (HIV) protease, which prevents HIV viral replication.17 When administered with ritonavir in combination antiretroviral therapy, darunavir significantly decreases viral load and increases CD4 cell counts, decreasing the morbidity and mortality of HIV infection.2,5,8 [DrugBank]

SMILES:

CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1

2D structures:  

3D structures: